PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Parent market • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2019 • Market size and forecast 2019-2024 • Market Outlook PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY APPLICATION • Market segmentation by application • Comparison by application • Infectious diseases - Market size and forecast 2019-2024 • Cancer - Market size and forecast 2019-2024 • Other diseases - Market size and forecast 2019-2024 • Market opportunity by application PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2019-2024 • Europe - Market size and forecast 2019-2024 • Asia - Market size and forecast 2019-2024 • ROW - Market size and forecast 2019-2024 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Increase in R&D of novel vaccine adjuvants • Development of nanoparticle adjuvants • Rising number of collaborations PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Agenus Inc. • Avanti Polar Lipids Inc. • Croda International Plc • CSL Ltd. • GlaxoSmithKline Plc • InvivoGen • Merck KGaA • OZ Biosciences SAS • SEPPIC SA • Vaxine Pty Ltd. PART 14: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Vendor key offerings Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2019 Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions) Exhibit 09: Global market: Year-over-year growth 2020-2024 (%) Exhibit 10: Five forces analysis 2019 Exhibit 11: Five forces analysis 2024 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2019 Exhibit 18: Application - Market share 2019-2024 (%) Exhibit 19: Comparison by application Exhibit 20: Infectious diseases - Market size and forecast 2019-2024 ($ millions) Exhibit 21: Infectious diseases - Year-over-year growth 2020-2024 (%) Exhibit 22: Cancer - Market size and forecast 2019-2024 ($ millions) Exhibit 23: Cancer - Year-over-year growth 2020-2024 (%) Exhibit 24: Other diseases - Market size and forecast 2019-2024 ($ millions) Exhibit 25: Other diseases - Year-over-year growth 2020-2024 (%) Exhibit 26: Market opportunity by application Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2019-2024 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2019-2024 ($ millions) Exhibit 31: North America - Year-over-year growth 2020-2024 (%) Exhibit 32: Top 3 countries in North America Exhibit 33: Europe - Market size and forecast 2019-2024 ($ millions) Exhibit 34: Europe - Year-over-year growth 2020-2024 (%) Exhibit 35: Top 3 countries in Europe Exhibit 36: Asia - Market size and forecast 2019-2024 ($ millions) Exhibit 37: Asia - Year-over-year growth 2020-2024 (%) Exhibit 38: Top 3 countries in Asia Exhibit 39: ROW - Market size and forecast 2019-2024 ($ millions) Exhibit 40: ROW - Year-over-year growth 2020-2024 (%) Exhibit 41: Top 3 countries in ROW Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Impact of drivers and challenges Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendors covered Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: Agenus Inc. - Vendor overview Exhibit 51: Agenus Inc. - Business segments Exhibit 52: Agenus Inc. - Organizational developments Exhibit 53: Agenus Inc. - Geographic focus Exhibit 54: Agenus Inc. - Key offerings Exhibit 55: Agenus Inc. - Key customers Exhibit 56: Avanti Polar Lipids Inc. - Vendor overview Exhibit 57: Avanti Polar Lipids Inc. - Business segments Exhibit 58: Avanti Polar Lipids Inc. - Organizational developments Exhibit 59: Avanti Polar Lipids Inc. - Key offerings Exhibit 60: Avanti Polar Lipids Inc. - Key customers Exhibit 61: Croda International Plc - Vendor overview Exhibit 62: Croda International Plc - Business segments Exhibit 63: Croda International Plc - Organizational developments Exhibit 64: Croda International Plc - Geographic focus Exhibit 65: Croda International Plc - Segment focus Exhibit 66: Croda International Plc - Key offerings Exhibit 67: Croda International Plc - Key customers Exhibit 68: CSL Ltd. - Vendor overview Exhibit 69: CSL Ltd. - Business segments Exhibit 70: CSL Ltd. - Organizational developments Exhibit 71: CSL Ltd. - Geographic focus Exhibit 72: CSL Ltd. - Segment focus Exhibit 73: CSL Ltd. - Key offerings Exhibit 74: CSL Ltd. - Key customers Exhibit 75: GlaxoSmithKline Plc - Vendor overview Exhibit 76: GlaxoSmithKline Plc - Business segments Exhibit 77: GlaxoSmithKline Plc - Organizational developments Exhibit 78: GlaxoSmithKline Plc - Geographic focus Exhibit 79: GlaxoSmithKline Plc - Segment focus Exhibit 80: GlaxoSmithKline Plc - Key offerings Exhibit 81: GlaxoSmithKline Plc - Key customers Exhibit 82: InvivoGen - Vendor overview Exhibit 83: InvivoGen - Product segments Exhibit 84: InvivoGen - Key offerings Exhibit 85: InvivoGen - Key customers Exhibit 86: Merck KGaA - Vendor overview Exhibit 87: Merck KGaA - Business segments Exhibit 88: Merck KGaA - Organizational developments Exhibit 89: Merck KGaA - Geographic focus Exhibit 90: Merck KGaA - Segment focus Exhibit 91: Merck KGaA - Key offerings Exhibit 92: Merck KGaA - Key customers Exhibit 93: OZ Biosciences SAS - Vendor overview Exhibit 94: OZ Biosciences SAS - Product segments Exhibit 95: OZ Biosciences SAS - Key offerings Exhibit 96: OZ Biosciences SAS - Key customers Exhibit 97: SEPPIC SA - Vendor overview Exhibit 98: SEPPIC SA - Product segments Exhibit 99: SEPPIC SA - Organizational developments Exhibit 100: SEPPIC SA - Key offerings Exhibit 101: SEPPIC SA - Key customers Exhibit 102: Vaxine Pty Ltd. - Vendor overview Exhibit 103: Vaxine Pty Ltd. - Business segments Exhibit 104: Vaxine Pty Ltd. - Key offerings Exhibit 105: Vaxine Pty Ltd. - Key customers Exhibit 106: Validation techniques employed for market sizing Exhibit 107: Definition of market positioning of vendors

Agenus Inc., Avanti Polar Lipids Inc., Croda International Plc, CSL Ltd., GlaxoSmithKline Plc, InvivoGen, Merck KGaA, OZ Biosciences SAS, SEPPIC SA, and Vaxine Pty Ltd.